Biogen $18.9 Million Settlement Over False Aduhelm Pricing and Medicare Coverage Claims

Biogen faced an investor backlash after controversy surrounding Aduhelm, a high-profile Alzheimer’s drug whose pricing and insurance coverage were major public concerns. In a June 8, 2021 investor call, the company and two executives were accused of making materially false or misleading statements about whether they were engaging payers on Aduhelm’s pricing and about how Medicare coverage would be handled following FDA approval. Because Aduhelm’s coverage prospects and cost-to-payers could strongly affect expected demand and revenue, the lawsuit alleged those claims helped keep Biogen’s stock price artificially inflated for investors who bought shares during a defined class period (June 8, 2021 through July 12, 2021). The significance of this case is that it reached an $18.9 million class action settlement over “securities” fraud allegations, rather than a full trial on the merits. Investors who purchased Biogen common stock in the class period may now file a claim for a pro rata cash payment depending on the number of valid claims, purchase timing, and how losses are calculated. This kind of securities litigation matters because it pushes public companies to be more precise and evidence-based in disclosures—especially when statements can influence market expectations about drugs, reimbursement, and regulatory pathways. Similar cases often arise when investors claim corporate announcements or investor materials mischaracterized commercialization risks, payer negotiations, or reimbursement likelihood, leading to alleged stock price distortion. Broader implications include heightened scrutiny under industry rules that govern how companies communicate with investors and how drug coverage is expected to work in practice. In the U.S., reimbursement for drugs is shaped by complex programs like Medicare fee-for-service and private payer policies, and public statements tied to coverage assumptions can trigger legal exposure if they’re overstated or unsupported. The settlement also underscores a recurring pattern in life sciences: when blockbuster drugs depend on payer acceptance, reimbursement expectations, and real-world coverage outcomes, even “forward-looking” or interpretive comments can become central in litigation if investors later argue the messaging was misleading, which is why this settlement attempt ended uncertainty and helped redirect disputes into a structured claims process where eligible shareholders can seek recovery based on court-approved allocation formulas and transaction documentation.